Talk:Tolperisone

This is the talk page for discussing improvements to the Tolperisone article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Tolperisone.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

comparativ study with thiocolcicoside[edit]

if any comparative study availabe please inform. —Preceding unsigned comment added by 115.117.157.182 (talk) 17:59, 3 February 2010 (UTC)[reply]

more information about tolperisone[edit]

http://www.japi.org/february_2010/Article_17.pdf ... half-life of tolperisone is 1,5 - 2,5 hours. — Preceding unsigned comment added by 178.235.75.252 (talk) 10:45, 4 August 2013 (UTC)[reply]

Interactions grossly understated[edit]

From the patient information leaflet (last revised: February/March 2013) of the Cypriot distributor (M. K. Stavrinos), section “warnings and precautions:”

Hypersensitivity reactions range from mild skin reactions to severe systemic reactions (e.g. allergic shock). The following groups have a higher risk of experiencing hypersensitivity reactions: women, patients of older age, and patients treated with other medication concurrently (mainly with NSAIDs), patients with drug allergy or allergic diseases or conditions (such as atopy: hay fever, asthma, atopic dermatitis with high serum IgE, urticaria) in the past history, and finally patients who suffer from viral infections during the course of the tolperisone treatment. Early signs of hypersensitivity include flushing, rush, severe itching of the skin, wheezing, difficulty breathing (with or without swelling of the face, lips, tongue, and/or throat), difficulty in swallowing, fast heartbeat, low blood pressure, fast decrease in blood pressure.

Note: This is not a direct quote from the leaflet. I can upload an image of the leaflet upon request.

Can someone with the necessary knowledge edit the interactions section please?

62.195.45.181 (talk) 17:35, 4 March 2016 (UTC)[reply]